The Medicare Chamber of Commerce in the latest analysis of the import and export of pharmaceuticals in the first half of 2011 and the outlook for the second half of the year pointed out that on April 30 this year, the EU’s 7-year sales transition for herbal medicines set in the “EU Traditional Herbal Registration Directive” announced in 2004 At the end of the period, since China did not register a successful Chinese patent medicine for 7 years, China's exports of proprietary Chinese medicine products to the EU have been greatly affected. Exports have dropped to 50% in the same period last year.

The EU has always been the largest vegetable drug market in the world, with annual sales of 10 billion euros, accounting for more than 40% of the world's plant drug market share. If you abandon this market, it will be a huge loss to Chinese medicine companies.

Liu Zhanglin, vice president of the China Medicare Association, said that the implementation of the new EU policy is still a certain process. Now that the United Kingdom has announced the suspension of imports of Chinese medicines, although some countries in Northern Europe do not have mandatory regulations, their distributors have stopped by themselves because of concerns about the future market prospects of Chinese medicine. Imports have brought shocks to the export of Chinese medicines.

However, Liu Zhanglin also pointed out that the good news is that many Chinese medicine companies now see the importance of the EU market. Lanzhou Foci Pharmaceuticals has formally submitted applications for registration of Chinese medicine products to the Swedish National Drug Administration, and there are also seven to eight companies ready to The EU submitted a registration application for Chinese medicine. At the same time, due to the mutual recognition of the drug law among EU member states, if one can apply for a successful registration in one country, it means that it will be able to obtain an “admittance permit” for sales in the EU’s pharmaceutical mainstream market.